As insurers roll out new plan designs for 2026, patients with chronic neurological conditions face shifting prior authorization requirements and network restrictions that could delay treatment access and increase out-of-pocket costs, with industry analysts estimating that administrative burdens related to prior authorizations consume approximately $23 billion annually across the U.S. Healthcare system, according to a 2025 Council for Affordable Quality Healthcare (CAQH) report.
How Prior Authorization Delays Are Impacting Neurology Care Access in 2026
NeurologyLive’s recent discussion with Mitzi Joi Williams, MD, and Carol Coleman highlights a growing bottleneck in patient care: prior authorization requirements for disease-modifying therapies in multiple sclerosis, epilepsy, and migraine management have increased in complexity and frequency since 2024. Data from the American Academy of Neurology (AAN) shows that nearly 68% of neurologists reported prior authorizations leading to treatment delays exceeding 14 days in Q1 2026, up from 52% in the same period of 2024. These delays are not merely administrative—they correlate with measurable clinical deterioration, particularly in relapsing-remitting MS patients where treatment interruptions beyond 30 days increase relapse risk by 22%, per a 2025 study in Neurology.
The Bottom Line
- Prior authorizations for neurology treatments now consume an average of 12 hours per physician weekly, contributing to burnout and reducing patient face-time by nearly 20%, according to Medscape’s 2026 Physician Compensation Report.
- Insurers including UnitedHealth Group (NYSE: UNH) and Elevance Health (NYSE: ELV) have expanded apply of AI-driven utilization management tools, which while reducing fraudulent claims by 9%, have increased denial rates for neurology specialty drugs by 11% YoY, per S&P Global Market Intelligence.
- Patients navigating these changes face average out-of-pocket costs of $4,800 annually for specialty neurology medications under high-deductible plans, a 15% increase from 2024 levels, based on Kaiser Family Foundation (KFF) data.
Market Implications: How Insurer Policies Are Shaping Neurology Drug Demand and Stock Performance
The ripple effects of tightening prior authorization protocols are evident in the financial performance of neurology-focused pharmaceutical companies. Biogen (NASDAQ: BIIB), whose flagship MS therapy Tysabri® accounts for roughly 22% of its $10.2B 2025 revenue, saw its Q1 2026 prescription volume grow just 3.1% YoY—well below the 8.5% analyst consensus—attributed in part to utilization management barriers. Similarly, Eli Lilly (NYSE: LLY) reported that prior authorizations delayed uptake of its migraine preventive Emgality® by an estimated 4–6 weeks in 20% of new prescriptions, contributing to a 5.2% shortfall in neurology segment revenue versus guidance.
“When prior auth requirements shift unpredictably, it doesn’t just frustrate patients—it distorts demand forecasting and creates inventory volatility for manufacturers. We’ve seen wholesalers increase safety stock by 15% to buffer against abrupt changes in payer behavior.”
Meanwhile, pharmacy benefit managers (PBMs) like CVS Health’s Caremark (NYSE: CVS) and Cigna’s Express Scripts (NYSE: CI) are leveraging their scale to negotiate steeper rebates from neurology drugmakers, with average net price concessions reaching 48% for specialty neurology agents in 2025, up from 41% in 2023, according to SSR Health LLC. These rebates, while lowering list prices, often increase administrative complexity as providers must navigate multiple tiers of step therapy and fail-first protocols.
Regulatory Scrutiny and Legislative Pushback Gain Momentum
Growing frustration over prior authorization delays has prompted legislative action at both state and federal levels. As of April 2026, 28 states have enacted laws limiting prior authorization turnaround times to 72 hours for urgent care and 5 days for standard requests, with penalties for non-compliance. At the federal level, the bipartisan Improving Seniors’ Timely Access to Care Act, which would require Medicare Advantage plans to use a standardized electronic prior authorization system, has gained 142 co-sponsors in the House and is expected to be marked up by the Ways and Means Committee in June 2026.
“Administrative waste in healthcare isn’t just a cost issue—it’s a care delay issue. When neurologists spend more time on paperwork than patient exams, the system fails its core purpose.”
These regulatory shifts are beginning to influence investor sentiment. Stocks of companies specializing in prior authorization automation—such as Change Healthcare (NASDAQ: CHNG) and Olive AI (private, but backed by General Catalyst and Oak HC/FT)—have seen increased institutional interest, with CHNG’s shares outperforming the S&P 500 Health Care Select Sector Index by 6.3% YTD as of April 2024, driven by expectations of accelerated adoption of real-time authorization APIs under proposed CMS interoperability rules.
What Patients Should Do Now: Practical Steps to Mitigate Access Barriers
For patients managing chronic neurological conditions, proactive engagement remains critical. Experts recommend: verifying annual plan changes during open enrollment (typically October–December), requesting electronic health record (EHR) integration with insurer portals to automate prior auth submissions, and leveraging manufacturer co-pay assistance programs—which, according to the Patient Advocate Foundation, covered an average of 62% of out-of-pocket costs for neurology specialty drugs in 2025. Filing expedited appeals—now mandated under most state laws to be resolved within 72 hours—can reduce average resolution time from 11 days to under 3 when initiated promptly.
| Metric | 2024 | 2026 (YTD) | Change |
|---|---|---|---|
| Avg. Prior auth processing time (neurology) | 9.2 days | 11.5 days | +25% |
| Prior auth denial rate for specialty neurology drugs | 18% | 22% | +4pp |
| Physician weekly time spent on prior auths | 9.1 hours | 12.0 hours | +32% |
| Out-of-pocket cost for neurology specialty drugs (annual) | $4,150 | $4,800 | +16% |
As insurers continue to refine utilization management strategies under pressure to control specialty drug trend—projected to grow at 8.7% annually through 2028 per IQVIA—the balance between cost containment and timely access will remain a defining tension in neurology care. Patients, providers, and payers alike must adapt to a landscape where administrative efficiency is no longer a back-office concern but a direct determinant of clinical outcomes.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
